Research Article

The Prognosis Role of AST/ALT (De Ritis) Ratio in Patients with Adult Secondary Hemophagocytic Lymphohistiocytosis

Guangli Yin,1 Changfeng Man,1 Shengen Liao,2 and Hongxia Qiu1,3

1Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing 210029, China
2Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China
3Department of Geriatric Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing 210029, China

Correspondence should be addressed to Hongxia Qiu; qhx9805@126.com

Received 14 July 2020; Revised 15 September 2020; Accepted 18 November 2020; Published 8 December 2020

Academic Editor: Settimio Rossi

Copyright © 2020 Guangli Yin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. Secondary hemophagocytic lymphohistiocytosis (sHLH) accompanied by liver involvement, characterized by hepatomegaly and increased liver enzymes, is usually associated with elevated mortality. However, the magnitude of these associations remains unknown. Our objective was to assess the associations of the aspartate transaminase/alanine transaminase (AST/ALT, De Ritis) ratio with overall survival among adult patients with sHLH.

Methods. A retrospective analysis was performed on 289 patients aged 18–86 years with complete serum transaminase data at diagnosis of sHLH. Multivariate Cox regression analyses and restricted cubic splines were conducted to address the association between the De Ritis ratio and the risk of mortality.

Results. The median De Ritis ratio for the entire study population was 1.34 (IQR: 0.84-2.29). After a median follow-up time of 60 (range 17-227.5) days, 205 deaths occurred. After fully adjusting for hepatomegaly, albumin, fibrinogen, EBV, ferritin, etiologies, and treatment strategies, the adjusted hazard ratios (HRs) with corresponding confidence intervals (CIs) of mortality for the 2st tertile and 3st tertile were 1.2 (0.8-1.7) and 1.6 (1.1-2.2), respectively (P < 0.01 for trends). Restricted cubic spline confirmed a linear association between the log2-transformed De Ritis ratio and the risk of mortality. Moreover, this trend persisted in subgroups with MHLH, hyperferrinaemia, sCD25 ≤ 20,000 ng/L, patients without EBV infection, and those received treatment.

Conclusions. The De Ritis ratio is a strong and independent predictor for overall survival in patients with sHLH. As a readily available biomarker in routine clinical practice, it is used to identify patients with sHLH with inferior overall survival.

1. Introduction

Adult secondary hemophagocytic lymphohistiocytosis (sHLH) is an immune-mediated life-threatening disease characterized by aberrant activation and proliferation of polyclonal T lymphocytes and macrophages, leading to a cytokine storm, haemophagocytosis, and multiorgan infiltration and dysfunction [1]. Owing to a lack of awareness of the severity of the disease and prognosis, a delay in prompt treatment contributes to the high mortality rates. Therefore, it is becoming more important to identify prognostic indicators among patients with sHLH. For clinical practice ascertainment, a potential prognostic indicator would generally have great potential if it could be determined in a standard fashion and was inexpensive and easily measured.

Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are well-known liver enzymes released by both hepatocellular cells and nonhepatocellular cells, such as damaged myocardial cells, kidney, and skeletal muscle [2]. They are identified as indicators of various diseases, including liver disease, cardiovascular disease, cancer, and multiple organ dysfunction [3] and its association with prognosis [4]. The ratio of serum AST and ALT was initially described by De Ritis and has been known as the De Ritis ratio [5]. Over the past several decades, it has subsequently been shown to be a useful prognostic predictor in critical
illness and malignant tumors, including acute myocardial infarction [6], cardiovascular surgery [7], metastatic renal cell carcinoma [8], and upper tract urothelial carcinoma [9].

Liver dysfunction is central in sHLH. Elevated liver enzymes, hepatomegaly, and coagulopathy are signs of liver involvement [10]. In fact, the inclusion of increased transaminase levels was supported by the 2009 ASH guidelines for the diagnosis of sHLH from Professor Filipovich [11]. Several observational studies indicated that patients with sHLH who had hepatic involvement had significantly worse overall survival than those patients without hepatic involvement [12, 13]. It is crucial for physicians to identify poor prognosis patients earlier after diagnosis and before treatment and to apply effective combination therapy. However, data identifying relevant hepatic prognostic factors for patients with sHLH are lacking. Thus, the aim of our study was to investigate the prognostic value of the De Ritis ratio in patients with sHLH.

2. Patients and Methods

2.1. Study Patients. This study was conducted by retrospectively reviewing clinical data from a total of 289 adult patients with sHLH who were diagnosed at the First Affiliated Hospital of Nanjing Medical University from September 2014 to December 2019. Our study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University (ChiCTR2000032421), and informed consent was obtained to review patient medical records. All eligible patients were assessed according to the Histiocytosis Society in 2004, and the Hscore criteria were further applied to support the diagnosis of sHLH. The exclusion criteria were as follows: (1) patients less than 18 years old, (2) patients without detailed serum aminotransaminase levels, (3) patients with a history of hepatitis or severe fatty liver, and (4) patients who refused any treatment. The detailed study flowchart is presented in Figure 1. This study was carried out in accordance with the Declaration of Helsinki and reported according to the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) statement.

2.2. De Ritis Ratio. Laboratory data were routinely analyzed in each patient by standard clinical testing methodology in our hospital biochemical laboratory, and the upper limits of normal aminotransaminases were set at 40 and 50 IU/L for AST and ALT, respectively. AST/ALT (the De Ritis ratio) was categorized in tertiles according to the distributions of the study population: 1st tertile ≤ 1.0, 1.0 < 2nd tertile ≤ 1.79, and 3rd tertile > 1.79.

2.3. Covariates. We included covariates that are major predictors of overall survival according to previous studies [14–16]. Detailed information on age, sex, complete blood cell counts, hepatosplenomegaly, and blood biochemical tests including triglycerides, lactate dehydrogenase (LDH), albumin (ALB), fibrinogen (FIB), ferritin, serum soluble interleukin-2 receptor (sIL-2R, sCD25), and β2-microglobulin (β2-MG) was reviewed through medical records. EBV was evaluated by both serology and EBV DNA real-time quantitative polymerase chain reaction (RQ-PCR) analysis. Bone marrow aspiration and biopsy samples were reviewed at the first diagnosis. Tumor or lymph node biopsy and PET/CT were identified as malignancy-associated hemophagocytic lymphohistiocytosis (MHLH) [17].

2.4. Endpoint and Follow-Up. The primary outcome was overall survival. The survival status of participants was confirmed with death records or a telephone call to the patients and patients’ relatives, and overall survival was calculated as the time in days from the sHLH diagnosis to the date of death from any cause or the last follow-up.

2.5. Treatments. 289 patients which include 165 MHLH and 124 non-MHLH. Among 165 patients, 128 (77.6%) had received systemic combination chemotherapy as initial therapy for sHLH, 33 patients were treated according to HLH-94 as initial therapy, and 4 patients with progressive multiple organ dysfunction who were treated with only high-dose immunoglobulin and glucocorticoid chemotherapy. In our 124 non-MHLH patients, 21 (16.9%) patients had HLH-94 therapy, 30 (24.2%) had received only glucocorticoid (GC) therapy combined high-dose immunoglobulin (IVIG), 24 (19.4%) had GC+IVIG+etoposide, 18 (14.5%) had GC+IVIG+etoposide+cyclosporine, 24 (19.4%) patients refused any remedies, and 7 (5.6%) patients only received anti-infective therapy. There were no differences in treatment regimens between three groups.

2.6. Statistical Analysis. Categorical variables are presented as frequencies and percentages. Comparisons across De Ritis ratio tertiles were performed using one-way ANOVA followed by the post hoc test (least significant difference) for continuous variables and chi-square statistics for categorical variables. Paired Spearman correlation coefficients between the De Ritis ratio and clinical characteristics were calculated. Kaplan-Meier curves for tertiles of the De Ritis ratio were plotted to display mortality rates. Adjusted survival curves are adjusted for covariates derived from the final model according to multivariable Cox proportional hazards models.

Univariate Cox regression analysis was used to estimate the relationship between potential predictors and survival status at long-term follow-up. Multivariable Cox regression with stepwise forward selection was performed to analyze the influence of relevant variables (variables with $P < 0.05$ in univariate Cox regression were subsequently entered into the model) on overall survival. The hazard ratio (HR) was estimated with 95% confidence intervals (CI), and the respective $P$ values were reported from these analyses. HRs of ferritin and sCD25 variables refer to increases per 1000 μg/L and 10,000 ng/L, respectively. We log2-transformed the De Ritis ratio because it was skewed. Restricted cubic splines with three knots placed at the 10th, 50th, and 90th percentiles (the number of knots was selected according to the Akaike information criterion) were generated to examine the nonlinear relationships of the log2-transformed De Ritis ratio with the risk of mortality after adjusting for confounding factors, and the tests for nonlinearity were calculated by Wald $\chi^2$
Consecutive eligible sHLH patients ($n = 304$)
Patients satisfy HLH 2004 criteria and further support the diagnosis by Hscore points criteria, age ≥ 18 years.

Excluded patients:
Participants with a clear history of hepatic disease ($n = 9$)
Participants with missing follow-up time ($n = 6$)

Study population ($n = 289$)
Patients with baseline serum transaminase available without a history of liver disease

Malignancy-associated HLH ($n = 165$)
Non-Malignancy-associated HLH ($n = 124$)

**Figure 1:** Consort diagram of enrolled patients. sHLH: secondary hemophagocytic lymphohistiocytosis.

**Table 1:** Baseline demographic, clinical, and laboratory characteristics of the study patients according to tertiles of AST/ALT (De-Ritis ratio).

|                        | 1 st tertile ($N = 97$) | 2 st tertile ($N = 95$) | 3 st tertile ($N = 97$) | $P$ value |
|------------------------|-------------------------|-------------------------|-------------------------|-----------|
| De Ritis ratio         | 0.68 (0.50-0.85)        | 1.34 (1.17-1.58)        | 2.89 (2.28-3.96)        | <0.001    |
| ALT, U/L               | 90.9 (52.0-193.2)       | 67.9 (37.3-147.9)       | 46.2 (26.9-98.4)        | <0.001    |
| AST, U/L               | 55.9 (32.2-125.9)       | 96.4 (49.6-196.6)       | 140.0 (81.40-288.0)     | <0.001    |
| Male, n (%)            | 58 (59.8)               | 65 (68.4)               | 56 (57.7)               | 0.271     |
| Age, years             | 49 (37-64)              | 55 (43-66)              | 58 (42-65)              | 0.074     |
| ANC, × $10^9$/L        | 1.13 (0.82-2.73)        | 0.98 (0.69-1.92)        | 0.89 (0.69-2.32)        | 0.132     |
| HB, g/L                | 89 (74-103)             | 85 (69-104)             | 83 (70-94)              | 0.277     |
| PLT, × $10^9$/L        | 61 (35-90)              | 41 (24-61)              | 36 (20-60)              | <0.001    |
| LDH, U/L               | 452 (336-660)           | 676 (382-1025)          | 1195 (683-1990)         | <0.001    |
| ALB, g/L               | 27.60 (5.01)            | 27.02 (5.47)            | 26.87 (4.59)            | 0.568     |
| TG, mmol/L             | 2.36 (1.60-3.57)        | 2.35 (1.63-3.27)        | 2.86 (2.00-4.43)        | 0.002     |
| FIB, g/L               | 1.66 (1.11-2.32)        | 1.44 (0.91-2.12)        | 1.46 (1.05-2.18)        | 0.466     |
| Ferritin, ug/L         | 3137 (1321-8024)        | 5043 (2193-14576)       | 6258 (1600-17400)       | 0.016     |
| sCD25, ng/L            | 31212 (17540-43915)     | 34687 (16915-51866)     | 37622 (17744-54064)     | 0.607     |
| Splenomegaly (%)       | 85 (87.6)               | 82 (86.3)               | 89 (91.8)               | 0.465     |
| Hepatomegaly (%)       | 15 (15.5)               | 21 (22.1)               | 16 (16.5)               | 0.437     |
| Lymphadenopathy (%)    | 42 (43.3)               | 56 (58.9)               | 53 (54.6)               | 0.08      |
| Hemophagocytic (%)     | 91 (93.8)               | 86 (90.5)               | 80 (82.5)               | 0.035     |
| HScore, points         | 224 (196-258)           | 239 (207-269)           | 244 (220-274)           | 0.011     |
| EBV infection (%)      | 45 (46.4)               | 56 (58.9)               | 45 (46.4)               | 0.134     |
| Etiology               |                         |                         |                         | 0.053     |
| MHLH (%)               | 46 (47.4)               | 57 (60.0)               | 62 (63.9)               |           |
| Non-MHLH (%)           | 51 (52.6)               | 38 (40.0)               | 35 (36.1)               |           |
| Chemotherapy (%)       | 86 (88.7)               | 88 (92.6)               | 84 (86.6)               | 0.39      |

Abbreviations: ALT: alanine transaminase; AST: aspartate transaminase; De-Ritis ratio: aspartate transaminase/alanine transaminase; ANC: absolute neutrophil count; HB: hemoglobin; PLT: platelet; LDH: lactate dehydrogenase; ALB: albumin; TG: triglyceride; FIB: fibrinogen; sCD25: soluble interleukin-2 receptor; β2-MG: beta-2-microglobulin; EBV: Epstein-Barr virus; MHLH: malignancy-associated hemophagocytic lymphohistiocytosis; Non-MHLH: nonmalignancy associated hemophagocytic lymphohistiocytosis.
We regarded the De Ritis ratio tertiles as a continuous variable in the same model to test for significant linear trends. Moreover, we performed stratified analyses to explore whether the association between the De Ritis ratio and overall survival was modified by ALB, FIB, ferritin, hepatomegaly, EBV, etiologies, and treatment intervention. Interaction analyses were tested between De Ritis ratio tertiles and all other covariates in stratified analyses.

All statistical analyses were performed with R software version 3.6.0 (R Foundation for Statistical Computing, Vienna, Austria) and STATA/MP statistical software (version 14.0; stataCorp, TX, USA), and two-sided $P$ values $<0.05$ were considered statistically significant.

3. Results

3.1. Distribution of the De Ritis Ratio and Patient Characteristics. Detailed baseline characteristics of 289 study participants stratified by tertiles of the De Ritis ratio are shown in Table 1. The median age of the participants was
53 (interquartile range, 41–64 years), and 61.9% were male. For the study population, the median De Ritis ratio level was 1.34 (0.84-2.29). Participants with higher levels of the De Ritis ratio had higher LDH, TG, ferritin, β2-MG, and Hscore points and a higher proportion of MHLH. In addition, PLT was significantly lower in patients with the 3rd tertile of the De Ritis ratio (P < 0.001). Interestingly, we observed that the 1st tertile of the De Ritis ratio individuals had a higher prevalence of hemophagocytes (Table 1). Additionally, the De Ritis ratio showed a strong positive correlation with LDH values (r = 0.502; P < 0.001), TG values (r = 0.190; P = 0.001), β2-MG (r = 0.159; P = 0.007), ferritin (r = 0.163; P = 0.005), and Hscore points (r = 0.160; P = 0.007). The De Ritis ratio was inversely associated with PLT (r = 0.232; P < 0.001) (Figure 2).

3.2. Associations of the De Ritis Ratio with Overall Survival.
After a median follow-up of 60 days (range 17-227.5), we observed 205 deaths (134 for MHLH and 71 for non-MHLH). The Kaplan–Meier survival curves for tertiles of the De Ritis ratio in patients were plotted (Figure 3). Patients in the 1st and 2nd tertiles had a similar risk of death (P = 0.056), while patients in the 3rd tertile had a significantly greater risk of death (HR = 1.8, 95% CI: 1.3–2.5, P = 0.001) compared with the 1st tertile; after further adjusting for confounding factors, the HRs with 95% CIs of mortality for the 2nd and 3rd tertiles were 1.2 (0.8-1.7) and 1.6 (1.1–2.2), respectively (P for trend < 0.01) (Table 2 and Figure 3). RCS plots showed a positive linear association between the log2-transformed De Ritis ratio and the risk of mortality in sHLH (Figure 4, P for nonlinearity =0.881). Meanwhile, a similar trend was also found in the MHLH group rather than the non-MHLH group when we further considered etiologies (Figure 5).

3.3. Subgroup Analysis. We performed stratified analyses between the De Ritis ratio and the risk of mortality by ALB, FIB, ferritin, hepatomegaly, EBV, etiologies, and treatment intervention. In the subgroup analyses, patients with ferritin > 10,000 μg/L, sCD25 ≤ 20,000 ng/L, those without EBV infection, MHLH, and patients who received therapeutic intervention had similar worse survival between the 1st tertile and 2nd tertile, while patients in the 3rd tertile of the De Ritis ratio had a significantly higher risk of death compared with the 1st tertile (Table 3). Although the interaction of the De Ritis ratio with etiologies was not significant, aetiology-stratified models suggested that the association of the De Ritis ratio and mortality was significant among patients with MHLH but not non-MHLH patients (Figure 6).

4. Discussion
To the best of our knowledge, this is the first study to assess the impact of baseline aspartate transaminase/alanine
transaminase (AST/ALT, De Ritis ratio) on sHLH patient outcomes before treatment. The De Ritis ratio has a strong impact on mortality, persisting regardless of adjusting treatment, etiologies, EBV, ferritin, albumin, fibrinogen, and hepatomegaly. Moreover, by restricted cubic spline (RCS) modeling, we also found a direct association between the De Ritis ratio and

Table 2: Uni- and multivariate Cox regression analyses of overall survival.

|                         | Unadjusted HR (95% CI) | P     | Adjusted HR (95% CI) | P    |
|-------------------------|------------------------|-------|----------------------|------|
| Male                    | 1.5 (1.1-2.0)          | 0.011 | 1.5 (1.1-2.0)        | 0.001|
| Age > 60 years          | 1.3 (0.9-1.7)          | 0.065 | 1.2 (0.8-1.7)        | 0.158|
| ANC > 1.0 × 10^9/L      | 1.2 (0.9-1.5)          | 0.294 | 1.2 (0.9-1.5)        | 0.394|
| HB < 90 g/L             | 1.4 (1.0-1.8)          | 0.030 | 1.4 (1.0-1.8)        | 0.030|
| PLT < 100 × 10^9/L      | 1.9 (1.2-3.0)          | 0.004 | 1.9 (1.2-3.0)        | 0.004|
| FIB ≤ 1.5 g/L           | 1.9 (1.4-2.5)          | <0.001| 1.4 (1.0-1.9)        | 0.031|
| LDH ≥ 2.5 × ULN         | 1.1 (0.9-1.5)          | 0.390 | 1.1 (0.9-1.5)        | 0.390|
| ALB < 25 g/L            | 1.7 (1.3-2.2)          | <0.001| 1.5 (1.1-2.0)        | 0.008|
| TG ≥ 3.0 mmol/L         | 1.2 (0.9-1.6)          | 0.244 | 1.2 (0.9-1.6)        | 0.244|
| Splenomegaly            | 1.1 (0.7-1.7)          | 0.651 | 1.1 (0.7-1.7)        | 0.651|
| Hepatomegaly            | 1.8 (1.3-2.5)          | 0.001 | 1.6 (1.1-2.2)        | 0.011|
| Lymphadenopathy         | 1.2 (0.9-1.5)          | 0.268 | 1.2 (0.9-1.5)        | 0.268|
| Hemophagocytosis        | 0.9 (0.6-1.3)          | 0.436 | 0.9 (0.6-1.3)        | 0.436|
| Ferritin > 10000ug/L    | 1.9 (1.4-2.6)          | <0.001| 1.9 (1.4-2.6)        | <0.001|
| sCD25 > 20000 ng/L      | 1.6 (1.1-2.1)          | 0.005 | 1.6 (1.1-2.1)        | 0.005|
| EBV infection           | 1.8 (1.3-2.4)          | <0.001| 1.5 (1.1-2.0)        | 0.009|
| MHLH                    | 1.8 (1.3-2.4)          | <0.001| 1.8 (1.3-2.4)        | <0.001|
| Chemotherapy            | 0.9 (0.6-1.4)          | 0.670 | 0.9 (0.6-1.4)        | 0.670|
| De-Ritis ratio          |                        |       |                      |      |
| ≤1.00                   | 1 (ref)                |       | 1 (ref)              |      |
| 1.01 < ratio ≤1.79      | 1.4 (1.0-2.0)          | 0.056 | 1.2 (0.8-1.7)        | 0.444|
| >1.80                   | 1.8 (1.3-2.5)          | 0.001 | 1.6 (1.1-2.2)        | 0.013|

Abbreviations: ANC: absolute neutrophil count; HB: hemoglobin; PLT: platelet; LDH: lactate dehydrogenase; ALB: albumin; TG: triglyceride; FIB: fibrinogen; sCD25: soluble interleukin-2 receptor; EBV: Epstein-Barr virus; MHLH: malignancy-associated hemophagocytic lymphohistiocytosis; De-Ritis ratio: aspartate transaminase/alanine transaminase; HR: hazards ratio; 95% CI: 95% confidence interval.

Figure 4: Cubic spline plot of the association between the log2-transformed De Ritis ratio and the risk of mortality among adult onset HLH. The solid line and dashed line represent the estimated hazard ratios and their corresponding 95% CIs. Analyses were adjusted for hepatomegaly, albumin (ALB), fibrinogen (FIB), EBV, ferritin, malignancy-associated HLH (MHLH), and treatment strategies.
mortality in the total cohort, similar to the MHLH and non-MHLH subgroups. Multivariable regression analysis and adjusted Kaplan-Meier curves also revealed a higher risk of mortality in patients with the highest De Ritis ratio. The De Ritis ratio provided incremental values for risk prediction beyond clinical risk factors. These results are consistent with prior findings of the De Ritis ratio and a high mortality rate in critical illness and various types of cancers.

**Figure 5:** Cubic spline plots of the association between the log₂-transformed De Ritis ratio and the risk of mortality among adult onset MHLH (a) and non-MHLH (b). Analyses were adjusted for hepatomegaly, albumin (ALB), fibrinogen (FIB), EBV, ferritin, malignancy-associated HLH (MHLH), and treatment strategies.

**Table 3:** Stratified associations between De Ritis ratio and overall survival.

| Subgroups          | 1st tertile OR (95% CI) | 2nd tertile OR (95% CI) | 3rd tertile OR (95% CI) | P for trend | P for interaction |
|--------------------|------------------------|-------------------------|-------------------------|-------------|-------------------|
| Gender             | 1 (ref)                | 0.8 (0.5-1.3)           | 1.4 (0.9-2.1)           | 0.175       | 0.874             |
| Male               |                        |                         |                         |             |                   |
| Female             | 1 (ref)                | 1.2 (0.6-2.5)           | 1.4 (0.7-2.8)           | 0.317       |                   |
| Age ≤ 60 years     | 1 (ref)                | 1.1 (0.7-1.8)           | 1.4 (0.9-2.2)           | 0.203       | 0.950             |
| Yes                |                        |                         |                         |             |                   |
| No                 | 1 (ref)                | 1.0 (0.5-2.0)           | 1.5 (0.8-2.7)           | 0.168       |                   |
| PLT ≤ 100 × 10⁹/L  | 1 (ref)                | 1.0 (0.7-1.5)           | 1.3 (0.9-1.9)           | 0.157       | 0.095             |
| Yes                |                        |                         |                         |             |                   |
| No                 | 1 (ref)                | 0.4 (0.07-2.6)          | 3.2 (0.6-16.9)          | 0.212       |                   |
| Ferritin > 10000μg/L | 1 (ref)              | 1.2 (1.0-4.6)           | 2.1 (1.0-4.6)           | 0.035       | 0.985             |
| Yes                |                        |                         |                         |             |                   |
| No                 | 1 (ref)                | 1.0 (0.7-1.6)           | 1.4 (0.9-2.1)           | 0.165       |                   |
| sCD25 > 20000 ng/L | 1 (ref)                | 0.8 (0.5-1.3)           | 1.1 (0.7-1.7)           | 0.470       | 0.249             |
| Yes                |                        |                         |                         |             |                   |
| No                 | 1 (ref)                | 1.6 (0.8-3.3)           | 2.6 (1.3-5.2)           | 0.009       |                   |
| EBV infection      | 1 (ref)                | 1.1 (0.7-1.8)           | 1.1 (0.7-1.8)           | 0.634       | 0.329             |
| Yes                |                        |                         |                         |             |                   |
| No                 | 1 (ref)                | 1.1 (0.6-2.0)           | 2.1 (1.2-3.6)           | 0.005       |                   |
| MHLH               | 1 (ref)                | 1.2 (0.7-1.9)           | 1.8 (1.1-2.8)           | 0.014       | 0.209             |
| Yes                |                        |                         |                         |             |                   |
| No                 | 1 (ref)                | 0.8 (0.4-1.5)           | 1.1 (0.6-1.9)           | 0.496       |                   |
| Chemotherapy       | 1 (ref)                | 1.2 (0.8-1.8)           | 1.5 (1.1-2.2)           | 0.024       | 0.748             |
| Yes                |                        |                         |                         |             |                   |
| No                 | 1 (ref)                | 0.04 (0.003-0.5)        | 1.4 (0.4-5.7)           | 0.188       |                   |

Analyses were adjusted for hepatomegaly, albumin (ALB), fibrinogen (FIB), EBV, ferritin, malignancy-associated HLH (MHLH), and treatment strategies when they were not stratified variables.
While in hematologic malignancies, the De Ritis ratio was reported only as an adverse event style after treatment [20, 21], such as leukaemia and lymphoma, and its association with mortality has not been researched. In our study, we found that an elevated De Ritis ratio has a significantly positive correlation with inferior overall survival.

Figure 6: Survival curves in patients with HLH according to De Ritis ratio tertiles. (a, b) Kaplan-Meier survival curves in MHLH and non-MHLH. (c, d) Adjusted survival curves in MHLH and non-MHLH: curves are adjusted for hepatomegaly, albumin (ALB), fibrinogen (FIB), EBV, ferritin, malignancy-associated HLH (MHLH), and treatment strategies.
Compared with the 1st tertile, the 2nd tertile and 3rd tertile were associated with a 20% and 60% increase in the risk of mortality, respectively. The Max study and the Lee study also showed similar findings in critically ill patients with cardiovascular disease [6, 7]. Furthermore, we also found a new prospective relationship between the De Ritis ratio and different clinical parameters for sHLH, which has a positive association with higher TG, increased ferritin, elevated LDH and even HScore points, and an inverse association with decreased PLT. Moreover, unadjusted and adjusted survival analysis also demonstrated that a higher De Ritis ratio predicted poor overall survival, the same as in the MHLH and non-MHLH subgroups. The present study was able to illustrate that the De Ritis ratio is a prognostic indicator.

The underlying pathophysiological mechanism of elevated transaminase and its prognostic value in patients with sHLH is still unclear. In patients with sHLH, activated lymphocytes and macrophages secrete high levels of pro- and anti-inflammatory cytokines and chemokines, leading to liver involvement and progressive multiple organ dysfunction syndrome [10, 22]. One possible speculation is that periportal lymphocytic infiltration could aberrantly damage liver cells and promote further mitochondrial dysfunction, resulting in the accumulation of serum transaminase [23, 24]. In addition, IFN-γ has been proven to be a key cytokine that drives disease development in sHLH [25], stimulates hepatic inflammation by increasing TNF and IL-6, and induces hepatocyte apoptosis via a BCL2-mediated pathway [26]. Moreover, an elevated level of AST compared with ALT is hypothesized to be associated with increased cancer cell high proliferative status and normal tissue damage and can result in the higher activation of circulating AST [4], in line with a large part of the distribution in our 165 patients with MHLH. Finally, elevated AST levels may indicate a hypoperfusion state due to the cytokine storm leading to multiorgan dysfunction syndrome because AST is widely expressed in various types of tissues, whereas ALT is enriched in liver tissues.

Studies focused on liver involvement, including hepatomegaly and elevated liver enzymes, have been reported to be associated with poor outcome in HLH [10, 16, 27]. Nevertheless, although the single measures of AST or ALT are associated with prognosis, they are susceptible to various related factors, such as alcoholic liver disease and skeletal muscle-related disease [28]. Calculating the AST/ALT ratio reflects the combination of AST and ALT and is a stable factor [29], thus making the De Ritis ratio to be a promising biomarker for HLH.

Our findings provide references that routine clinical laboratory assays such as liver function tests can be used to identify patients at higher risk of death while applying an advanced evaluation for sHLH. On the one hand, in our study, an De Ritis ratio in the 3rd tertile had the worst overall survival outcome. This leads us to the hypothesize that the De Ritis ratio might be a particularly valuable tool in identifying the highest risk patients with sHLH. Moreover, 3rd tertile of the De Ritis ratio had lower platelet levels, higher TG, increased ferritin, and elevated LDH in terms of laboratory findings, which are related to disease activation and hyper-inflammatory status that have also been observed as being associated with a worse prognosis in other studies [10, 15]. In these patients, it may provide clinical guidance that timely multidisciplinary discussion of initiating HLH-directed immune suppressants and more support treatment is needed prior to the finalised results of specialized assays. In addition, the use of the De Ritis ratio also has the advantage of being an easily assessable biomarker at a low cost. However, there are several limitations in our study. First, this is a retrospective and single-centre study, and the results are subject to potential bias. Second, although a broad set of covariates was included in regression models, unmeasured confounding by additional factors could also play a role.

In conclusion, the De Ritis ratio is an independent prognostic factor in patients with sHLH. Further studies are warranted.

Data Availability
To request access to the data, please contact the corresponding author, who is the principal investigator of the study and responsible for the consortium database.

Ethical Approval
All procedures in studies were performed in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Conflicts of Interest
The authors declare that they have no competing interests.

Authors’ Contributions
GLY and HXQ designed the experiment. GLY performed the experiments. GLY, CFM, and HXQ organized the clinical materials. GLY and SGL performed the data analysis. GLY wrote the paper. All authors contributed to the final approval of the manuscript.

Acknowledgments
This work was supported by the National Natural Science Foundation of the People’s Republic of China [No. 81570175].

References
[1] S. J. Carter, R. S. Tattersall, and A. V. Ramanan, “Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment,” Rheumatology, vol. 58, no. 1, pp. 5–17, 2019.
[2] A. K. Lim, “Abnormal liver function tests associated with severe rhabdomyolysis,” World Journal of Gastroenterology, vol. 26, no. 10, pp. 1020–1028, 2020.
[3] D. Zhao, Y. Zhang, Z. Yin, J. Zhao, D. Yang, and Q. Zhou, “Clinical predictors of multiple organ dysfunction syndromes in pediatric patients with scrub typhus,” Journal of Tropical Pediatrics, vol. 63, no. 3, pp. 167–173, 2016.
[4] J. Wu, L. Chen, Y. Wang, W. Tan, and Z. Huang, “Prognostic value of aspartate transaminase to alanine transaminase (De Ritis) ratio in solid tumors: a pooled analysis of 9,400 patients,” Oncotargets and Therapy, vol. 12, pp. 5201–5213, 2019.

[5] F. de Ritis, L. Mallucci, M. Coltori, G. Giusti, and M. Caldera, “Anicteric virus hepatitis in a closed environment as shown by serum transaminase activity,” Bulletin of the World Health Organization, vol. 20, pp. 589–602, 1959.

[6] M. Steininger, M.-P. Winter, T. Reiberger et al., “De-Ritis ratio improves long-term risk prediction after acute myocardial infarction,” Journal of Clinical Medicine, vol. 7, no. 12, p. 474, 2018.

[7] J. S. Nam, W. J. Kim, S. M. An et al., “Age-dependent relationship between preoperative serum aminotransferase and mortality after cardiovascular surgery,” Aging (Albany NY), vol. 11, no. 20, pp. 9060–9074, 2019.

[8] M. Kang, J. Yu, H. H. Sung et al., “Prognostic impact of the pretreatment transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma,” International Journal of Urology, vol. 25, no. 6, pp. 596–603, 2018.

[9] K. Mori, F. Janisch, H. Mostafaei et al., “Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy,” Urologic Oncology: Seminars and Original Investigations, vol. 38, no. 6, pp. 601.e17–601.e24, 2020.

[10] B. Beken, S. Aytaç, G. Balta et al., “The clinical and laboratory evaluation of familial hemophagocytic lymphohistiocytosis and the importance of hepatic and spinal cord involvement: a single center experience,” Haematologica, vol. 103, no. 2, pp. 231–236, 2018.

[11] A. H. Filipovich, “Hemophagocytic lymphohistiocytosis (HLH) and related disorders,” Hematology, vol. 2009, no. 1, pp. 127–131, 2009.

[12] K. N. Koh, H. J. Im, N. G. Chung et al., “Clinical features, genetics, and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in Korea: report of a nationwide survey from Korea: Histiocytosis working party,” European Journal of Haematology, vol. 94, no. 1, pp. 51–59, 2015.

[13] S. L. Guthery and J. E. Heubi, “Liver involvement in childhood histiocytic syndromes,” Current Opinion in Gastroenterology, vol. 17, no. 5, pp. 474–478, 2001.

[14] J. H. Yoon, S. S. Park, Y. W. Jeon et al., “Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy,” Haematologica, vol. 104, no. 2, pp. 269–276, 2019.

[15] F. Li, Y. Yang, F. Jin et al., “Clinical characteristics and prognostic factors of adult hemophagocytic syndrome patients: a retrospective study of increasing awareness of a disease from a single-center in China,” Orphanet Journal of Rare Diseases, vol. 10, no. 1, p. 20, 2015.

[16] M. Arca, L. Fardet, L. Galcier et al., “Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide,” British Journal of Haematology, vol. 168, no. 1, pp. 63–68, 2015.

[17] J. Wang, D. Wang, Q. Zhang et al., “The significance of pre-therapeutic F-18-FDG PET-CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable,” Journal of Cancer Research and Clinical Oncology, vol. 142, no. 4, pp. 859–871, 2016.

[18] J. Riedl, F. Posch, G. Prager et al., “The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study,” Annals of Oncology, vol. 30, Supplement 4, p. iv78, 2019.

[19] A. Bezan, E. Mrsic, D. Krieger et al., “The preoperative AST/ALT (De Ritis) ratio represents a poor prognostic factor in a cohort of patients with nonmetastatic renal cell carcinoma,” Journal of Urology, vol. 194, no. 1, pp. 30–35, 2015.

[20] S. Srivastava, D. Jones, L. L. Wood et al., “A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed or refractory non-Hodgkin lymphoma,” Biology of Blood and Marrow Transplantation, vol. 17, no. 7, pp. 987–994, 2011.

[21] V. M. Klimek, E. K. Dolezal, L. Smith, G. Soff, and S. D. Nimer, “Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia,” Leukemia Research, vol. 36, no. 5, pp. 570–574, 2012.

[22] G. E. Janka and K. Lehmborg, “Hemophagocytic lymphohistiocytosis: pathogenesis and treatment,” Hematology, vol. 2013, no. 1, pp. 605–611, 2013.

[23] S. L. Yang, X. J. Xu, Y. M. Tang et al., “Associations between inflammatory cytokines and organ damage in pediatric patients with hemophagocytic lymphohistiocytosis,” Cytokine, vol. 85, pp. 14–17, 2016.

[24] A. Ost, S. Nilsson-Arndor, and J. I. Henter, “Autopsy findings in 27 children with haemophagocytic lymphohistiocytosis,” Histopathology, vol. 32, no. 4, pp. 310–316, 2001.

[25] G. Principe, C. Bracaglia, I. Caiello et al., “The interferon-γ pathway is selectively up-regulated in the liver of patients with secondary hemophagocytic lymphohistiocytosis,” PloS One, vol. 14, no. 12, article e0226043, 2019.

[26] B. Knight, R. Lim, G. C. Yeo, and J. K. Olynyk, “Interferon-γ exacerbates liver damage, the hepatic progenitor cell response and fibrosis in a mouse model of chronic liver injury,” Journal of Hepatology, vol. 47, no. 6, pp. 826–833, 2007.

[27] H. Trottettestam, A. C. Horne, M. Aricò et al., “Chemoinmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol,” Blood, vol. 118, no. 17, pp. 4577–4584, 2011.

[28] M. Shibata, K. Nakajima, R. Higuchi, T. Iwane, M. Sugiyama, and T. Nakamura, “High concentration of serum aspartate aminotransferase in older underweight people: results of the Kanagawa Investigation of the Total Check-Up Data from the National Database-2 (KITCHEN-2),” Journal of Clinical Medicine, vol. 8, no. 9, p. 1282, 2019.

[29] Y. H. Cho, J. E. Hwang, H. S. Chung et al., “The De Ritis (aspartate transaminase/alanine transaminase) ratio as a predictor of oncological outcomes in patients after surgery for upper urinary tract urothelial carcinoma,” International Urology and Nephrology, vol. 49, no. 8, pp. 1383–1390, 2017.